Dupilumab prevents nasal epithelial function alteration by IL‐4 in vitro: Evidence for its efficacy
International Forum of Allergy & Rhinology · 2024-08 · 14 (8) · 1337-1349
DOI: 10.1002/alr.23343 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Forum of Allergy & Rhinology, online erschienen am 11.03.2024. Verfasst von Maxime Fieux und 12 weiteren Autor:innen. Beteiligte Einrichtung: Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Service d'ORL, d'Otoneurochirurgie et de Chirurgie Cervico-Faciale, Pierre Bénite, France. Hauptthemen laut MEDLINE: Interleukin-4, Nasal Mucosa, Antibodies, Monoclonal, Humanized, Interleukin-13. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: la Société Française d'Oto-Rhino-Laryngologie et de Chirurgie Cervico-Faciale (SFORL), le Collège Français d'Oto-Rhino-Laryngologie et de Chirurgie Cervico-Faciale (CFORL&CCF), Amplifon.
Abstract (Originalsprache)
Background
Chronic rhinosinusitis with nasal polyp (CRSwNP) is a typical type 2 inflammation involving interleukin (IL)‐4 and IL‐13. Dupilumab is a fully human monoclonal antibody targeting IL‐4 receptor α subunit, thereby blocking signaling by both cytokines. Our hypothesis was that IL‐4 and IL‐13, by inducing a severe epithelial dysregulation, are involved in CRSwNP pathogenesis. This study aimed to evaluate the in vitro direct effect of IL‐4, IL‐13, and dupilumab on nasal epithelial functions.
Methods
Nasal polyps and control mucosa from 28 patients, as well as human nasal epithelial cells (HNEC) from 35 patients with CRSwNP were used. Three major epithelial functions were investigated: the epithelial barrier function (characterized by transepithelial electrical resistance measurements and tight junction protein expression), the ciliary motion (characterized by the ciliary beating efficiency index), and wound healing (characterized by the wound repair rate) under various stimulations (IL‐4, IL‐13, and dupilumab). The main outcome was a significant change in epithelial functions following exposure to IL‐4, IL‐13, and dupilumab for 48 h in the basal media.
Results
IL‐4 (1, 10, and 100 ng/mL) but not IL‐13 induced a significant decrease in occludin and zonula‐occludens protein expression, ciliary beating efficiency, and wound repair rate in HNEC. Dupilumab (0.04 mg/mL) had no effect on HNEC and specifically restored all epithelial functions altered when cells were exposed to a 48‐h IL‐4 stimulation.
Conclusion
Dupilumab, in vitro, restored epithelial integrity by counteracting the effect of IL‐4 on the epithelial barrier (increased epithelial permeability, decreased ciliary beating efficiency, and decreased wound repair rate).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Service d'ORL, d'Otoneurochirurgie et de Chirurgie Cervico-Faciale, Pierre Bénite, France.
- Faculté de Médecine et de Maïeutique Lyon Sud-Charles Mérieux, Université de Lyon, Université Lyon 1, Lyon, France.
- CNRS EMR 7000, Créteil, France.
- INSERM, IMRB, Univ Paris Est Créteil, Créteil, France.
- Laboratoire Inflammation Tissus Epithéliaux et Cytokines, UR15560, Université de Poitiers, Poitiers, France.
- Service ORL, Chirurgie Cervico-Maxillo-Faciale et Audiophonologie, Centre Hospitalier Universitaire de Poitiers, Poitiers, France.
ORCID-Profile: Maxime Fieux, Florent Carsuzaa, Sophie Bartier, Bruno Louis
Förderung
- la Société Française d'Oto-Rhino-Laryngologie et de Chirurgie Cervico-Faciale (SFORL)
- le Collège Français d'Oto-Rhino-Laryngologie et de Chirurgie Cervico-Faciale (CFORL&CCF)
- Amplifon
Zitieren
APA
Fieux, M., Carsuzaa, F., Bellanger, Y., Bartier, S., Fournier, V., Lecron, J. C., Bainaud, M., Louis, B., Tringali, S., Dufour, X., Coste, A., Favot, L., & Bequignon, E. (2024). Dupilumab prevents nasal epithelial function alteration by IL‐4 in vitro: Evidence for its efficacy. International Forum of Allergy & Rhinology, 14(8), 1337-1349. https://doi.org/10.1002/alr.23343
Vancouver
Fieux M, Carsuzaa F, Bellanger Y, Bartier S, Fournier V, Lecron JC, et al. Dupilumab prevents nasal epithelial function alteration by IL‐4 in vitro: Evidence for its efficacy. International Forum of Allergy & Rhinology. 2024;14(8):1337-1349. doi:10.1002/alr.23343
BibTeX
@article{Fieux2024,
author = {Fieux, Maxime and Carsuzaa, Florent and Bellanger, Yvan and Bartier, Sophie and Fournier, Virginie and Lecron, Jean Claude and Bainaud, Matthieu and Louis, Bruno and Tringali, Stéphane and Dufour, Xavier and Coste, André and Favot, Laure and Bequignon, Emilie},
title = {Dupilumab prevents nasal epithelial function alteration by IL‐4 in vitro: Evidence for its efficacy},
journal = {International Forum of Allergy & Rhinology},
year = {2024},
volume = {14},
number = {8},
pages = {1337--1349},
doi = {10.1002/alr.23343}
}
EUVIMED